Summary
3M Company (MMM) reported its full-year 2021 financial results in its 10-K filing, showcasing resilience and growth amidst supply chain challenges and global economic shifts. The diversified technology company, operating across Safety and Industrial, Transportation and Electronics, Health Care, and Consumer segments, experienced broad-based organic growth, with total sales increasing by 9.9% year-over-year, driven by an 8.8% organic sales increase. Despite increased raw material and logistics costs, the company managed to offset these pressures through higher selling prices and continued productivity efforts. The Health Care segment demonstrated particularly strong performance with a 20.1% increase in operating income. While the company navigated inflationary pressures and supply chain disruptions, including the impact of extreme weather events, it maintained a strong financial position. Net income attributable to 3M was $5.92 billion, and the company returned significant capital to shareholders through $2.2 billion in share repurchases and $3.4 billion in dividends. Management highlighted its commitment to investing in growth, productivity, and sustainability, with plans for increased capital spending in 2022. However, investors should remain aware of the ongoing risks, including potential impacts from global economic conditions, public health crises, foreign currency fluctuations, and significant legal and regulatory proceedings, particularly those related to fluorochemicals (PFAS) and product liability.
Financial Highlights
56 data points| Revenue | $35.35B |
| Cost of Revenue | $18.80B |
| Gross Profit | $16.56B |
| R&D Expenses | $1.20B |
| SG&A Expenses | $7.20B |
| Operating Expenses | $27.99B |
| Operating Income | $7.37B |
| Interest Expense | $488.00M |
| Net Income | $5.92B |
| EPS (Basic) | $10.23 |
| EPS (Diluted) | $10.12 |
| Shares Outstanding (Basic) | 579.00M |
| Shares Outstanding (Diluted) | 585.30M |
Key Highlights
- 13M reported a 9.9% increase in total sales to $35.4 billion for the full year 2021, with organic sales growing by 8.8%.
- 2The Health Care segment showed robust growth, with sales up 8.4% and operating income increasing by 20.1%.
- 3The company faced increased raw material and logistics costs, which impacted operating income margins, but managed these through higher selling prices and productivity initiatives.
- 43M returned $5.6 billion to shareholders through dividends ($3.4 billion) and share repurchases ($2.2 billion) in 2021.
- 5Significant legal and environmental matters, particularly those involving PFAS (per- and polyfluoroalkyl substances), continue to be a key area of focus and potential risk for the company.
- 6The company maintained a strong liquidity profile with $4.8 billion in cash, cash equivalents, and marketable securities at year-end 2021.
- 7The Safety and Industrial segment saw a 9.8% sales increase, though operating income decreased by 3.3% due to higher costs and litigation expenses.